|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |
Abstract |
|---|
|
|
|---|
In an earlier study, we showed that a recombinant adenovirus vector with deletions in the E1 and E3 regions of the viral genome (AV1LacZ4) induces expression of interleukin (IL)-8 in A549 cells (a human
respiratory cell line). IL-8 can be induced through several pathways, including activation by IL-1. We tested
the hypothesis that the induction of IL-8 by the AV1LacZ4 adenovirus is accomplished by means of the
IL-1/IL-8 activation pathway, which could be blocked by IL-1 receptor antagonist (IRAP). Viral infections
of A549 cells were performed at a multiplicity of infection (MOI) of 50 in the presence and absence of
IRAP (50 ng/ml). A549 cells were also stimulated with tumor necrosis factor (TNF)-
(100 ng/ml), a
known stimulant of IL-8, in the presence and absence of IRAP. IL-8 expression was evaluated by Northern
blot analysis and enzyme-linked immunosorbent assay. Levels of IL-8 protein and messenger RNA
(mRNA) were greater in the infected cells than in the uninfected ones at 24, 48, and 96 h (P < 0.01). Virus-infected cells treated with IRAP expressed 75% less IL-8 mRNA and protein (P < 0.01) than did untreated cells, whereas IRAP pretreatment of TNF-
-stimulated cells did not affect IL-8 production. IL-1
production by the virus-infected cells was detectable by concentration of the supernatants and reverse transcription-polymerase chain reaction. We conclude that IL-8 is produced by virus vector-infected cells,
partly through IL-1 activation that can be downregulated by IRAP.
| |
Introduction |
|---|
|
|
|---|
The most common lethal autosomal recessive disease of the human Caucasian population is cystic fibrosis (CF) (1), with an estimated incidence of 1:2,500. The basic abnormality in CF is a defect of cyclic adenosine monophosphate (cAMP)-regulated chloride secretion by epithelial cells (2). The CF transmembrane conductance regulator (CFTR) gene, located on chromosome 7 at position 7q31, encodes a cAMP-dependent chloride channel in the apical membrane of epithelial cells of the airway and other tissues (5). Following the cloning and sequencing of the CFTR gene in 1989 (2, 6), correction of the basic genetic defect in airway cells of patients with CF by somatic cell gene therapy became feasible. A number of gene delivery systems for this purpose are currently under consideration, including the use of recombinant adenovirus vectors. We evaluated the utilization of a replication-deficient recombinant adenovirus as a viral vector for delivering normal CFTR complementary DNA (cDNA) to airway epithelial cells, with the goal of expressing this gene and correcting the chloride channel defect in the respiratory tract of individuals with CF (7).
A recombinant adenovirus with deletions in the E1 and
E3 regions of the viral genome is efficient as a vector in
transferring CFTR cDNA into airway epithelial cells in
vitro (8). This replication-deficient adenovirus vector is
particularly attractive because it has a natural tropism for
airway epithelial cells (13). Introduction of this replication-deficient recombinant adenovirus into the lungs of
animals resulted in a nonspecific inflammatory response (14). The instillation of a recombinant adenovirus
vector containing the Rous sarcoma virus long-terminal-repeat promoter, which drove either a nuclear-targeted
gene (AV1LacZ4) or CFTR cDNA (Av1Cf2) in the cotton rat lung, resulted in neutrophil-dominated alveolar and peribronchial cellular infiltration at 3 d after administration (18). The nature of the infiltrate changed from neutrophil-dominated during the first few days to macrophage-
and mononuclear cell-dominated by Day 10. Instillation of
the same vector into the lungs of macaque monkeys was
also associated with a mild to moderate inflammation, the
intensity of which was dose-dependent (15). A related recombinant adenovirus vector, utilizing a cytomegalovirus
(CMV) promoter and expressing the
-galactosidase gene
(LacZ), induced a moderate inflammation predominantly
in the distal lung parenchyma of the baboon (16). Nonhuman primates exposed to an adenovirus vector developed
an inflammatory response at 3 d after exposure. Analysis of bronchoalveolar lavage fluid (BALF) for interleukin
(IL)-8 showed increased levels of this cytokine in animals
that received a high dose of the vector, suggesting that
IL-8 might play a role in the vector-induced inflammation
seen in these animals (15). We have shown that in vitro
cellular transduction of A549 bronchial epithelial cells by
Av1LacZ4, at a multiplicity of infection (MOI) of 50 virus
particles per cell, resulted in gene delivery to 80 ± 5% of
the cell monolayer. Furthermore, by 24 h, IL-8 messenger RNA (mRNA) transcript and neutrophil chemoattractant
activity in supernatants from Av1LacZ4-transduced cells
were significantly higher than in supernatants from uninfected control cells. IL-8 mRNA and protein levels remained increased for 96 h (19). These findings show that
gene delivery to the airway epithelium with the serotype 5 adenovirus (Ad5)-based expression vector results in IL-8
gene activation in these cells, a process that may contribute to understanding of the inflammatory host response to
the vector (14, 16, 20).
A549 pulmonary epithelial cells express IL-8 after stimulation with tumor necrosis factor (TNF)-
, phorbol myristate acetate (PMA), and IL-1 (20). A549 cells are a valid
model for studing the events occurring in airway epithelial
cells. CMV and respiratory syncytial virus (RSV) infections are known to induce production of IL-1 in mononuclear cells (21, 22), and RSV infection also induces IL-8
gene activation in epithelial cells (23, 24). We theorized
that a potential mechanism for IL-8 induction by virus infection is through primary induction of IL-1, which then induces IL-8. If IL-1 does induce IL-8, the specific IL-1 receptor antagonist (IRAP) could therefore block IL-8 production. The blocking of IL-8 induction by IRAP has been
reported by several investigators (25, 26). The present
study was done to test the hypothesis that the induction of
IL-8 in A549 cells by the adenovirus vector Av1LacZ4 is
inhibited by preincubation with human IRAP.
| |
Materials and Methods |
|---|
|
|
|---|
Cell Culture and Experimental Protocol
A549 pulmonary epithelial cells derived from a human alveolar cell carcinoma (American Type Culture Collection,
Rockville, MD) were seeded into tissue-culture plates at a
density of 5 × 104 cells/cm2 in Dulbecco's modified Eagle's
medium (DMEM) (Gibco/BRL, Life Technologies Inc.,
Grand Island, NY) containing 10% lipopolysaccharide (LPS)-free fetal bovine serum (FBS) (Hyclone, Logan, UT),
100 U/ml penicillin, and 100 mg/ml streptomycin (Sigma
Chemical Co., St. Louis, MO). The cells were grown to
confluence at 37°C in humidified 95% air/5% CO2. On the
day of infection, the cell supernatants were discarded and
fresh medium was added. The recombinant adenovirus vector was then added to the monolayer according to the
infection protocol. Before the adenovirus vector was
added, half of the plates were treated with 50 ng/ml of
IRAP. Other A549 cells were stimulated with recombinant human IL-1
(hIL-1
) (Endogen, Boston, MA) in
concentrations of 0.2, 2, 20, and 200 pg/ml. For blocking experiments, cell cultures were pretreated with IRAP protein (a kind gift from Synergen, Boulder, CO) at concentrations of 10, 100, 1,000, and 10,000 pg/ml, which were applied 90 min before implementing the adenoviral infection
or adding the cytokine stimulant. TNF-
at a concentration of 100 U/ml (Endogen) was used as positive control.
At 24, 48, and 96 h, cell-free supernatants were collected and cells were trypsinized and counted with a hemocytometer, and the cell viability was determined by trypan blue
exclusion. Cells were also harvested for RNA extraction.
Virus Vector Construct
The Av1LacZ4 vector carries a nuclear-targeted LacZ
gene. Av1LacZ4 is a first generation, E1a, E3-deleted recombinant adenovirus vector derived from Ad5. The heterologous minigene consists of the Rous sarcoma virus
promoter driving expression of the nuclear targeted
-galactosidase encoding sequence. The construction, purification, and titration of Av1LacZ4 have been described
elsewhere (14). The vector was stored in virus dialysis
buffer (10 mM Tris-HCl [pH 7.4], 1 mM MgCl2, 10% glycerol) at
70°C until used.
Infection Protocol
Immediately before infection, Av1LacZ4 was thawed and added to the cells in fresh DMEM containing 2% FBS (Hyclone), 100 U/ml penicillin, and 100 mg/ml streptomycin. The vector concentration was calculated on the basis of a desired MOI of 50/cell and a total estimated cell density of 2.5 × 105/cm2 when the monolayer was confluent. This concentration was determined from previous cell-count studies (data not shown). After 90 min of exposure to the virus vector, the FBS concentration in the medium was corrected to 10%.
Enzyme-Linked Immunosorbent Assay
IL-8 and IL-1
were quantitated with a direct sandwich
enzyme-linked immunosorbent assay (ELISA) method
(20, 29). Each test sample was assayed in triplicate. A standard titration curve was obtained by making serial dilutions of human recombinant IL-8 protein (R&D Systems,
Minneapolis, MN). Light absorption was measured at 450 nm on a THERMOmax microplate reader (Molecular Devices, Inc., Menlo Park, CA). The lower limit of sensitivity
for this ELISA was 20 pg/ml.
Concentration of Supernatants
Concentration of supernatants from control cells, cells infected with the virus vector, and cells treated with TNF-
was done with Centriprep concentrators (Amicon Inc.,
Beverly, MA). In essence, 15 ml of supernatant was concentrated in a Centriprep-10 through a three-step centrifugation procedure. The final-to-original concentration ratio
was 15:1.
Membrane Preparation
Membrane preparations for control cells, cells infected
with the virus vector, and cells treated with TNF-
were
isolated after 96 h of culture, through a modification of a
detergent solubilization method described by Weissman
(30).
Northern Blot Analysis
Total RNA was recovered by modification of the acid phenol extraction method of Chomczynski and Sacchi (20,
31). Lysis buffer (4 M guanidinium isothiocyanate, 25 mM
sodium citrate [pH 7], 0.1 M
-mercaptoethanol) was
added to each well to extract RNA (0.5 ml/well). Purified
RNA was stored at
80°C until further purification was
done with Phase Lock Gell II (5 Prime
3 Prime, Inc.,
Boulder, CO) to optimize the recovery of RNA from the
organic extraction according to the manufacturer's directions. RNA was quantified by measuring absorbance at
260 nm after dilution in 10 mM Tris, 0.1 mM ethylenediaminetetraacetic acid (EDTA) (pH 8.0). Aliquots of 15 mg
of total RNA were denatured with 6 M glyoxal (40%
ethanedial in aqueous solution) (Sigma), dimethylsulfoxide, and 0.1 M sodium phosphate (pH 7.0). The glyoxal
solution was deionized (32). Samples containing equal
amounts of RNA were fractionated on a 1.2% agarose gel
and transferred to nylon membranes (Hybond, Amersham
International, Amersham, UK). After crosslinking, the
Hybond filters were stained with 1% methylene blue in
0.3 M sodium acetate to assess the integrity of the RNA
and to verify the uniformity of loading.
The Hybond filters were then prehybridized for 2 h at
65°C in 5× saline-sodium phosphate-EDTA (SSPE) (1×
SSPE = 150 mM NaCl, 10 mM NaH2PO4, and 1 mM
EDTA [pH 7.4], 5× Denhardt's solution (1× Denhardt's
solution is 0.02% bovine serum albumin, 0.02% Ficoll, 0.02% polyvinylpyrrolidone), 0.1% sodium dodecylsulfate
(SDS), and 100 µg/ml salmon sperm DNA. Hybridization
was performed overnight in a similar prehybridization solution with a [32P]deoxycytosine triphosphate ([32P]dCTP)-
labeled 0.3-kb complementary DNA (cDNA) clone of human IL-8 mRNA (a kind gift from Dr. Ivan J. D. Lindley,
Sandoz Forschungsinstitut, Austria), or a 0.4-kb 3' untranslated region (UTR) fragment of a human
-actin
cDNA clone.
The cDNAs were [32P]dCTP-labeled (Amersham) with
a random-primer DNA labeling system (T7 QuickPrime
Kit; Pharmacia LKB Biotechnology, Piscataway, NJ), and
the oligonucleotide (for Southern blot analysis) was labeled by 5' end labeling. After hybridization, blots were
washed twice at room temperature with solutions of increasing stringency (standard saline citrate with 0.1%
SDS) and at increasing temperature until an adequate
background reading was obtained. All filters were wrapped
in plastic wrap and exposed to a phosphorimaging storage screen for 20 min before peak volume quantitation, which
was done with a PhosphorImager (Molecular Dynamics,
Sunnyvale, CA), using ImageQuant software (33). Additionally, autoradiograms for IL-8 and
-actin were generated by exposure of the filters to Kodak XAR-2 film (Eastman Kodak, Rochester, NY) at
80°C overnight.
Duplicate Hybond filters were hybridized with 32P-labeled IL-8 cDNA. After quantification with the PhosphorImager and autoradiography, the same filters were stripped
and rehybridized with 32P-labeled human
-actin cDNA.
In order to normalize for loading quantities, the data were
expressed as:
|
(1) |
which represents the ratio of IL-8-mRNA from treated
cells (txt) to IL-8-mRNA from control cells (Co), divided
by the ratio of
-actin units of mRNA from treated cells to
-actin units of mRNA from control cells.
Reverse Transcription-Polymerase Chain Reaction
Reverse transcription (RT) was done with Moloney murine leukemia virus reverse transcriptase, after which the
polymerase chain reaction (PCR) was performed (34),
with both procedures done according to the manufacturer's directions (Gibco/BRL, Life Technologies, Inc.,
Grand Island, NY), using a Perkin-Elmer (Norwalk, CT)
PCR apparatus. In brief, the RT sample had a volume of
19.5 µl and the reaction was performed for 1 h at 37°C.
Two microliters of reverse-transcribed product were used
for the PCR (30 cycles) reaction of the pro-IL-1 sequence.
From this PCR product, 2 µl were used for a nested PCR
reaction of the secreted IL-1 sequence. A standardization
protocol was implemented with
-actin PCR as internal
control. The primer used for the pro-IL-1
upstream
primer was 5'-GCCCTAAACAGATGAAGTGTCC-3',
and that for the downstream primer was 5'-ATTGCATGGTGAAGTCAGTTATATC-3'. For the nested PCR of the secreted sequence of IL-1
, a 5'-GCTGATGGCCCTAAACAG-3' upstream primer and 5'-GAAGACGGGCATGTTTTC-3' downstream primer were used. Primers for IL-1
were 5'-GTAAGCTATGGCCCACTC-3'
and 5'-GAAATAGTTCTTAGTGCCGTG-3' (sense and
antisense, respectively). RT-PCR analysis for pro-IL-1
with subsequent nested PCR for the secreted sequence of
IL-1
was done with total RNA from uninfected A549 (control) and infected cells at 96 h of culture, together with U937
cells untreated and treated with PMA (10 ng/ml) for 24 h.
An IL-1 cDNA was used as a positive control for the PCR.
Southern Blot Analysis
Agarose gel (1%) electrophoresis was done with 20 µl of the PCR product. An aliquot of DNA mass ladder (4 µl; Gibco/BRL, Life Technologies Inc., Gaithersburg, MD) was added for the recognition of bands.
The agarose gel was denatured by soaking it for 20 min
in 0.4 N NaOH, 1 M NaCl, transferring the bands to nylon
membranes (Hybond), and cross-linking. The Hybond membranes were prehybridized and hybridized according to
the same used for the Northern blot analysis, with an IL-1
oligonucleotide.
LacZ Staining of Cytospin Preparations
Cells were removed from the culture plates by trypsin digestion, washed with phosphate-buffered saline (PBS),
and resuspended at a concentration of 25 × 105 cells/200 µl.
Cytospin preparations were made on a cytocentrifuge (Shandon Southern, Sewickley, PA) at 700 rpm for 5 min,
air dried for 1 h, and stored at
70°C until used. Slides
were fixed with 0.5% glutaraldehyde for 10 min at room
temperature, washed with PBS, and stained for 3 h with
5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside (X-Gal)
stain (5 mM potassium ferrous cyanide, 5 mM potassium ferric cyanide, 2 mM magnesium chloride, 1 mg/ml X-Gal,
0.02% NP40 in PBS). Av1LacZ4 expresses a nuclear-targeted LacZ gene. Therefore, A549 cells transduced by
Av1LacZ4 have blue-staining nuclei after histochemical
staining for
-galactosidase.
Statistical Analysis
Statistical analysis, with replicate experiments as covariants (n = 3 experiments with three replicates), was done at each time point by analysis of variance, and subsequent analysis of mean pairs was done with Student's t test. Data are presented as means ± SD, and results were considered significant at P < 0.05.
| |
Results |
|---|
|
|
|---|
IL-8 Gene Expression in Infected Cells
Av1LacZ4 infection of the A549 epithelial monolayer at
an MOI of 50 produced increased IL-8 gene expression.
IL-8 gene expression, as measured from mRNA levels and
compared with that in uninfected cells, was increased by
7.1 ± 6.2-fold at 24 h (P = 0.11), by 6.1 ± 4.4-fold at 48 h
(P = 0.2), and by 9.3 ± 5.3-fold at 96 h (P < 0.06) (Figure
1). Stimulation of A549 cells with TNF-
at a concentration of 100 U/ml increased the IL-8 mRNA level by 24 h to
6.2-fold that of unstimulated cells, after which the levels decreased to near baseline by 96 h (data not shown).
|
Demonstration of Extracellular IL-8
A549 cells constitutively produced low levels of IL-8. Infection of A549 cells with virus vector resulted in a significant increase in IL-8 secretion above baseline levels in a
time-dependent fashion (Figure 2). At 24 h, the IL-8 level
in the virus-infected group was 0.47 ± 0.08 ng/ml, whereas
the level in the uninfected group was 0.17 ± 0.05 ng/ml (P < 0.001). At 48 h, the IL-8 level in the virus-infected group
was 0.96 ± 0.18 ng/ml, whereas the level in the uninfected
group was 0.46 ± 0.12 (P < 0.001), and by 96 h the levels
in the two groups were 4.8 ± 0.22 ng/ml and 1.4 ± 0.09 ng/ml, respectively (P < 0.001) (Figure 2). The TNF-
- stimulated cells had a significantly greater concentration
of IL-8 at all time points (7.1 ± 0.2 ng/ml at 24 h; 6.3 ± 0.3 ng/ml at 48 h; 7.9 ± 0.1 ng/ml at 96 h).
|
Pretreatment of Virus Vector-Infected A549 Airway Epithelial Cells with IRAP
IRAP downregulated by one third the IL-8 gene activation induced by the virus vector, with the decrease reaching significance at 96 h (Figure 1). Protein levels of IL-8
were also significantly downregulated at both 48 and 96 h
(P < 0.05) (Figure 2). In one experiment, IL-8 protein levels were standardized by cell counting, which showed consistency. IRAP did not affect IL-8 mRNA induced by
TNF-
(data not shown), and IRAP alone did not have
any affect on the constitutive production of IL-8.
Blocking Effect of IRAP on IL-8 Gene Activation in
IL-1
-Stimulated Respiratory Cells
IL-1
could not be detected with ELISA in the supernatant from infected cells. To demonstrate that IL-1
concentrations below the lower limit of the ELISA were able
to induce mRNA and secretion of IL-8, we stimulated
A549 cells with IL-1
at concentrations of from 0.2 to 20 pg/ml. There was a dose-related increase in IL-8 expression with increasing concentrations of IL-1
(Figure 3). A
dose of IL-1
as low as 0.2 pg/ml was able to induce a statistically significant increase in IL-8 concentration as compared with the concentration for unstimulated cells. Pretreatment of IL-1
-stimulated cells with IRAP reduced
IL-8 production in a dose-related manner (Figure 3).
|
RT-PCR and Southern Blot Hybridization for
IL-1
from Infected Cells
The expected 713-bp size band for pro-IL-1
was identified, and a 404-bp band was identified for the IL-1
cDNA
after the nested PCR (Figure 4). We found increased (and
sustained) expression of IL-1
mRNA in the infected cells
as compared with the untreated uninfected cells. Recognition of bands for IL-1
(pro- and cDNA) was done
through Southern blot analysis with a 300-bp cDNA for IL-1
(Figure 5). No bands were seen after RT-PCR analysis done with primers for IL-1
.
|
|
Determination of IL-1
Production by ELISA of
Concentrated Supernatants and
Membrane Preparations
We were unable to detect IL-1
in unconcentrated supernatants. The concentrated supernatants from vector-infected
cells showed significantly higher levels of IL-1
at 96 h (37 ± 1 pg/ml) than did concentrated supernatants from uninfected
control cells, in which IL-1
was undetectable.
Av1LacZ4 Transduction Rate
The rate of transduction of A549 cells with Av1LacZ4 at 24, 48, and 96 h after exposure to the virus was 47.5 ± 15.6%, 80 ± 5.09%, and 85.5 ± 3.93%, respectively, indicating efficient transduction by the virus.
| |
Discussion |
|---|
|
|
|---|
The results of this study support the hypothesis that the
adenovirus vector Av1LacZ4 partly induces IL-8 transcription and secretion in A549 cells through IL-1
induction. By blocking the IL-1 receptor with IRAP and partly
inhibiting the adenovirus vector-induced expression and
release of IL-8, we showed the relationship of IL-1 to IL-8
induction. Other researchers have showed a mechanism of
IL-8 production through primary IL-1 induction. Lukacs
and colleagues (34) demonstrated significantly decreased
levels of IL-8 on Day 5 of culture after IRAP pretreatment
at 25 ng/ml. DeForge and coworkers (26) addressed the
question of whether IRAP would suppress IL-8 produced
by LPS-stimulated human blood monocytes, and found
downregulation of IL-8 by IRAP. Kaplanski and associates (27) verified a similar mechanism of IL-8 production through IL-1 in activated platelets, and Porat and coworkers (34) showed that Borrelia burgdorferi induces IL-8 by
IL-1 induction, which can be regulated by IRAP.
We were able to demonstrate expression and secretion
of IL-1
by virus-infected cells through RT-PCR, and to
measure secreted IL-1
protein in concentrated supernatants from treated cells, although we failed to detect IL-1
in the supernatants of infected cell with the usual ELISA
technique. Smith and colleagues (35) have also reported
IL-1
production by A549 cells. We showed that a concentration below 15 pg/ml of IL-1
in the supernatant was sufficient to induce IL-8 production, and that the resulting
IL-8 levels could be reduced by pretreating the cells with
IRAP. Furthermore, we found that the adenovirus vector
used in our study induced sustained expression of IL-1
and IL-8 for up to 96 h, which contrasts markedly with the
peak of cytokine activity occurring at 24-48 h when A549
cells were stimulated with IL-1
or TNF-
. RT-PCR analysis for IL-1
mRNA and ELISA measurements of concentrated supernatants for secreted IL-1
polypeptide
showed that this cytokine was present for up to 96 h after
infection of A549 cells, whereas no mRNA or antigenic
protein was found in untreated cells. The viral effect on
IL-1
induction in cells infected in vitro is consistent with
the finding in previous studies that showed a direct stimulation of IL-1
and IL-1
production by other viruses, such
as CMV and RSV (21, 36, 37).
The immune response to wild type adenovirus is modulated by several viral gene products (13). It is not clear
how the virus stimulates the induction of IL-1. IL-1, TNF,
and PMA induce IL-8 by inducing a nuclear factor (NF)-
B-like factor that complexes the region between
80
and
71 bp of the IL-8 promoter (38). Another factor,
binding to the region between
94 and
81 bp, and which
was proposed (39) as a pathway for cooperative IL-1 gene
expression by IL-1, TNF, or PMA, is an NF-IL-6-like factor coupled to CCAAT/enhancer binding protein (C/EBP).
The IL-6 gene is inducible by IL-1 or TNF (13). IL-1 induces translocation of the NF-
B-like factor, replacing the
weaker C/EBP-like factor and leading to expression of IL-8.
Our current study provides an important contribution
to the understanding of viral induction of IL-8 by demonstrating IL-1 activation (which activates translocation of
the NF-
b-like factor [39] and leads to IL-8 gene expression). IRAP could be effective in the treatment of patients
with viral infections when IL-8 induction is the main pathway inducing inflammation. Specifically, IRAP can be
given prophylactically to patients undergoing gene therapy in order to prevent the activation of IL-8 as well as
other effects of IL-1. McCoy and associates (40) were unable to show blockage of inflammation induced by the virus vector AdRSV, which contained a human cDNA
IRAP. We performed a 90-min preincubation of A549 cells with IRAP before infection or IL-1 stimulation.
Moreover, we used IRAP in a 50-fold excess over IL-1
concentrations, owing to the potent inflammatory effect of
low concentrations of IL-1 (0.2 pg/ml). The peak levels of
expression of IRAP in McCoy and colleagues' study were
5.5 ng/ml in the BALF of male CBA/J mice, but they did
not measure the level of IL-1
in the fluid. To be able to
block the proinflammatory effects of IL-1
, IRAP has to be present in a sufficient excess (41, 42). It can be hypothesized that if McCoy and colleagues' mice had been pretreated with IRAP or actually inoculated with virus having
a promoter that amplifies the transcription of human
IRAP in order to induce enough copies of the IRAP protein, it would have been present in a sufficient excess to
block IL-1.
Other models of induction of IL-8 could be studied by using IRAP to block IL-8 production and demonstrate that such production occurs through IL-1 activation. Such models would be useful for studying mechanisms of inflammation in different diseases in which IL-8 is expressed.
In summary, our study contributes to the understanding and modulation of virus-induced inflammation by suggesting a role for IL-1 in early induction of the cytokine network that leads to airway inflammation after the administration of adenoviral vectors.
| |
Footnotes |
|---|
Abbreviations: complementary DNA, cDNA; cystic fibrosis transmembrane regulator, CFTR; interleukin, IL; interleukin-1 receptor antagonist, IRAP; polymerase chain reaction, PCR; reverse transcription-polymerase chain reaction, RT-PCR.
(Received in original form September 10, 1998 and in revised form February 25, 1999).
Acknowledgments: This study was supported by grant 51832 from the National Heart, Lung, and Blood Institute, the Center for Gene Therapy for Cystic Fibrosis, and the Cystic Fibrosis Foundation.
| |
References |
|---|
|
|
|---|
1. Boat, T. F, M. J. Welsh, and A. L. Beaudet. 1989. Cystic fibrosis. In The Metabolic Basis of Inherited Disease. C. R. Scriver, A. Beaudet, W. S. Sly, and D. Valle, editors. McGraw-Hill, New York. 2649-2680.
2.
Kerem, B.,
J. M. Rommens,
J. A. Buchanan,
D. Markiewicz,
T. K. Cox,
A. Chakravarti,
M. Buchwald, and
L. C. Tsui.
1989.
Identification of the cystic fibrosis gene: genetic analysis.
Science
245:
1073-1080
3.
Rommens, J. M.,
M. C. Iannuzzi,
B. Kerem,
M. L. Drumm,
G. Melmer,
M. Dean,
R. Rozmahel,
J. L. Cole,
D. Kennedy, and
N. Hidaka.
1989.
Identification of the cystic fibrosis gene: chromosome walking and jumping.
Science
245:
1059-1065
4. Riordan, J. R., J. M. Rommens, B. Kerem, N. Alon, R. Rozmahel, Z. Grzelczak, J. Zielenski, S. Lok, N. Plavsic, and J. L. Chou. 1989. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245:1066-1073. (Published erratum appears in Science 1989;245:1437).
5. Bear, C. E., C. H. Li, N. Kartner, R. J. Bridges, T. J. Jensen, M. Ramjeesingh, and J. R. Riordan. 1992. Purification and functional reconstruction of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell 68: 809-818 [Medline].
6. Tsui, L.C., J. Rommens, B. Kerem, R. Rozmahel, J. Zielenski, D. Kennedy, D. Markiewicz, N. Plavsic, J. L. Chou, and D. Bozon. 1991. Molecular genetics of cystic fibrosis. Adv. Exp. Med. Biol. 290: 9-17 [Medline].
7. Wilmott, R. W., J. A. Whitsett, and B. C. Trapnell. 1993. Gene therapy of cystic fibrosis utilizing a replication deficient recombinant adenovirus vector to deliver the human cystic fibrosis transmembrane regulator cDNA to the airways. A phase I study. 1994 Hum. Gene Ther. 5: 1019 .
8. Trapnell, B. C.. 1993. Adenoviral vectors for gene transfer. Advanced Drug Delivery Rev. 12: 185-199 .
9. Rosenfeld, M. A., K. Yoshimura, B. C. Trapnell, K. Yoneyama K, E. R. Rosenthal, W. Dalemans, M. Fukayama, J. Bargon, L. E. Stier, and L. Stratford-Perricaudet. 1992. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68:143-155.
10. Welsh, M. J., Principal investigator. 1992. Cystic fibrosis gene therapy using an adenovirus vector: in vivo safety and efficacy in the nasal epithelium. Fed. Regist. (57 FR 49584).
11. Wilson, J. M., Principal investigator. 1992. Gene therapy of cystic fibrosis lung diseases using E1-deleted adenovirus: a phase 1 trial. Fed. Regist. (57 FR 49584).
12. Rich, D. P., L. A. Couture, L. M. Cardoza, V. M. Guiggio, D. Armentano, P. C. Espino, K. Hehir, M. J. Welsh, A. E. Smith, and R. J. Gregory. 1993. Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis. Hum. Gene Ther. 4: 461-476 [Medline].
13. Wadell, G. 1994. Adenoviruses. In The Encyclopedia of Virology. R. G. Webster and A. Granoff, editors. Academic Press, San Diego, CA.
14. Brody, S. L., M. Metzger, C. Danel, M. A. Rosenfeld, and R. G. Crystal. 1994. Acute response of non-human primates to airway delivery of an adenovirus vector containing the human cystic fibrosis transmembrane conductance regulator cDNA. Hum. Gene Ther. 5: 821-836 [Medline].
15. Wilmott, R. W., R. S. Amin, C. R. Perez, S. E. Wert, G. Keller, G. P. Boivin, R. Hirsch, J. Inocencio, P. Lu, S. F. Reising, S. Yei, J. A. Whitsett, and B. C. Trapnell. 1996. Safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lungs of non-human primates. Hum. Gene Ther. 7: 301-318 [Medline].
16. Simon, R. H., J. F. Engelhardt, Y. Yang, M. Zepeda, S. W. Pendleton, M. Grossman, and J. M. Wilson. 1993. Adenovirus-mediated transfer of the CFTR gene to lung of non-human primates: toxicity study. Hum. Gene Ther. 4: 771-780 [Medline].
17. Brody, S. L., M. E. Metzger, and R. G. Crystal. 1993. Repeat airway administration of replication deficient recombinant adenovirus vectors to non-human primates is safe and effective. Am. Rev. Respir. Dis. 147: A544 .
18. Yei, S., N. Mittereder, S. Wert, J. A. Whitsett, R. W. Wilmott, and B. C. Trapnell. 1994. In vivo evaluation of the safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lung. Hum. Gene Ther. 5: 731-744 [Medline].
19. Amin, R. S., R. Wilmott, Y. Schwarz, B. Trapnell, and J. Stark. 1995. Replication-deficient adenovirus induces expression of Interleukin-8 by airway epithelial cells in vitro. Hum. Gene Ther. 6: 145-153 [Medline].
20. Standiford, T. J., S. L. Kunkel, M. A. Basha, S. W. Chensue, J. P. Lynch, G. B. Toews, J. Westwick, and R. M. Strieter. 1990. Interleukin-8 gene expression by a pulmonary epithelial cell line: a model for cytokine networks in the lung. J. Clin. Invest. 86: 1945-1953 .
21. Dudding, L., S. Haskill, B. D. Clark, P. E. Auron, S. Sporn, and E. S. Huanf. 1989. Cytomegalovirus infection stimulates expression of monocyte-associated mediator genes. J. Immunol. 143: 3343-3352 [Abstract].
22. Panuska, J. R., M. I. Hertz, H. Taraf, A. Villani, and N. M. Cirino. 1992. Respiratory syncytial virus infection of alveolar macrophages in adult transplant patients. Am. Rev. Respir. Dis. 145: 934-939 [Medline].
23. Becker, S., J. Quay, and J. Soukup. 1991. Cytokine (tumor necrosis factor, IL-6, and IL-8) production by respiratory syncytial virus-infected human alveolar macrophages. J. Immunol. 147: 4307-4312 [Abstract].
24. Becker, S., H. S. Koren, and D. C. Henke. 1993. Interleukin-8 expression in normal nasal epithelium and its modulation by infection with respiratory syncytial virus and cytokines tumor necrosis factor, interleukin-1, and interleukin-6. Am. J. Respir. Cell Mol. Biol. 8: 20-27 .
25.
Lukacs, N. W.,
S. L. Kunkel,
M. D. Burdick,
P. M. Lincoln, and
R. M. Strieter.
1993.
Interleukin-1 receptor antagonist blocks chemokine production
in the mixed lymphocyte reaction.
Blood
82:
3668-3674
26. DeForge, L. E., D. E. Tracey, J. S. Kenney, and D. G. Remick. 1992. Interleukin-1 receptor antagonist protein inhibits interleukin-8 expression in lipopolysaccharide-stimulated human whole blood. Am. J. Pathol. 140: 1045-1054 [Abstract].
27.
Kaplanski, G.,
R. Porat,
K. Aiura,
J. K. Erban,
J. A. Gelfand, and
C. A. Dinarello.
1993.
Activated platelets induce endothelial secretion of interleukin-8 in vitro via an interleukin-1-mediated event.
Blood
81:
2492-2495
28. Hornbeck, P. 1993. Enzyme-linked immunosorbent assay. In Current Protocols in Immunology. F. Ausubel et al., editors. Wiley-Greene, New York. 11.3.1.
29. Weissman, A. M. 1991. Solubilization of cellular proteins. In Current Protocols in Immunology. J. E. Cologan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober, editors. National Cancer Institute. National Institutes of Health, Bethesda, MD. Section I, Unit 8.1:811-819.
30. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162: 156-159 [Medline].
31. Hames, B. D., and S. J. Higgins. 1985. Nucleic acid hybridisation, a practical approach. In The Practical Approach, Series 14. D. Rickwood and B. D. Hames, editors. IRL Press, Washington DC. 90.
32. Johnston, R. F., S. C. Pickett, and D. L. Barker. 1990. Autoradiography using storage phosphor technology. Electrophoresis 11: 355-360 [Medline].
33. Kawasaki, E. S. 1990. Amplification of rank. In PCR Protocols: A Guide to Methods and Applications. M. A. Innis, D. H. Gelfand, J. J. Sninsky, and T. J. White, editors. Academic Press, San Diego, CA. 21.
34. Porat, R., D. D. Poutsiaka, L. C. Miller, E. V. Granowitz, and C. A. Dinarello. 1992. Interleukin-1 (IL-1) receptor blockade reduces endotoxin and Borrelia burgdorferi-stimulated IL-8 synthesis in human mononuclear cells. FASEB J. 6: 2482-2486 [Abstract].
35. Smith, D. R., S. L. Kunkel, T. J. Standiford, S. W. Chensue, M. W. Rolfe, M. B. Orringer, R. I. Whyte, M. D. Burdick, J. M. Danforth, A. R. Gilbert, and R. M. Strieter. 1993. The production of interleukin-1 receptor antagonist by human bronchogenic carcinoma. Am. J. Pathol. 143: 794-803 [Abstract].
36. Lewis, M. A., J. S. Slater, L. I. Leverone, and A. E. Campbell. 1990. Enhancement of interleukin-1 activity by murine cytomegalovirus infection of a macrophage cell line. Virology 178: 452-460 [Medline].
37.
Patel, J. A.,
M. Kunimoto,
T. C. Sim,
R. Garofalo,
T. Eliott,
S. Baron,
O. Ruuskanen,
T. Chonmaitree,
P. L. Ogra, and
F. Schmalstieg.
1995.
Interleukin-1
mediates the enhanced expression of intracellular adhesion molecule-1 in pulmonary epithelial cells infected with respiratory syncytial virus.
Am. J. Respir. Cell Mol. Biol.
16:
602-609
.
38.
Mukaida, N.,
Y. Mache, and
K. Matsushima.
1990.
Cooperative interaction
of NF-
B- and C/EBP-like factor binding elements in activating the interleukin-8 gene by pro-inflammatory cytokines.
J. Biol. Chem.
265:
21128-21133
39.
Shimizu, H.,
K. Mitomo,
T. Watanabe,
S. Okamoto, and
K. Yamamoto.
1990.
Involvement of a NF-
B-like transcription factor in the activation of
the interleukin-6 gene by inflammatory lymphokines.
Mol. Cell. Biol.
10:
561-568
40. McCoy, R. D., B. L. Davidson, B. J. Roessler, G. B. Huffnagle, and R. H. Simon. 1995. Expression of human interleukin-1 receptor antagonist in mouse lungs using a recombinant adenovirus: effects on vector-induced inflammation. Gene Ther. 7: 437-442 .
41. Arend, O. W. P., H. G. Welgus, H. G. Thompson, and S. P. Eisenberg. 1990. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J. Clin. Invest. 85: 1694-1697 .
42. Kent, S., R. M. Bluthe, R. Dantzer, A. J. Hardwick, and K. W. Kelley. 1992. Different receptor mechanisms mediate the pyrogenic and behavioral effects of interleukin 1. Proc. Natl. Acad. Sci. USA. 89:19, 9117-9120.
This article has been cited by other articles:
![]() |
K. Chakrabarty, W. Wu, J. L. Booth, E. S. Duggan, N. N. Nagle, K. M. Coggeshall, and J. P. Metcalf Human Lung Innate Immune Response to Bacillus anthracis Spore Infection Infect. Immun., August 1, 2007; 75(8): 3729 - 3738. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Wallace, M. Linker-Israeli, D. Hallegua, S. Silverman, D. Silver, and M. H. Weisman Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study Rheumatology, July 1, 2001; 40(7): 743 - 749. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Proc. Am. Thorac. Soc. | Am. J. Respir. Crit. Care Med. |